Southport Residents Acknowledged for Participation in Pioneering Cancer Trial

Hundreds of people in Southport are being thanked for taking part in the NHS-Galleri trial – the world's largest research study of a multi-cancer early detection blood test.

The leader of Cheshire and Merseyside Cancer Alliance is thanking Southport people who were some of the 22,000 participants in the region, as trial blood test appointments come to an end.
Mobile clinics have visited locations across the region over almost three years, including Southport, to collect blood samples from volunteers taking part. This month marks the conclusion of three rounds of blood sample appointments for participants.

Cheshire and Merseyside was selected along with seven other regions to support the trial. Around 140,000 volunteers enrolled from many different socio-economic and ethnic backgrounds across England.
Jon Hayes, Managing Director of Cheshire and Merseyside Cancer Alliance, said: “Participating in clinical research has the potential to improve the way that cancer is detected, and we are hugely grateful to people in Southport who volunteered for this research.”

The trial aims to see if a multi-cancer early detection (MCED) blood test, called Galleri, can help detect cancer early when used alongside population screening programmes. Finding cancer early often means it is easier to treat. Volunteers were all aged 50 to 77 years old at the point of enrolling onto the trial and had not been diagnosed or treated for cancer in the last three years.

Prof Richard Neal, Chief Investigator for the trial, said: “Volunteers have played their part and we are grateful for their time and commitment. But the work of researchers continues with results due to be published in 2026. We’ll continue to collect information from the NHS so that researchers can assess whether there are significant differences between the group of participants whose blood was screened with the Galleri test and participants whose blood was not tested.”

Early research has shown that an MCED test could help to detect cancers that are typically difficult to identify including cancers for which there is no national screening programme. 

The NHS-Galleri trial is being run by the Cancer Research UK Cancer Prevention Trials Unit at King’s College London in partnership with the NHS and healthcare company, GRAIL, which has developed the Galleri test. 
The trial is operating with the support of eight NHS Cancer Alliances across England that span Cheshire and Merseyside, Greater Manchester, the North East and North Cumbria, West Midlands, East Midlands, East of England, Kent and Medway, and South East London.